Halogen bonds form the basis for selective P-TEFb inhibition by DRB.

[1]  Weiliang Zhu,et al.  C-X...H contacts in biomolecular systems: how they contribute to protein-ligand binding affinity. , 2009, The journal of physical chemistry. B.

[2]  Weiliang Zhu,et al.  Halogen bonding--a novel interaction for rational drug design? , 2009, Journal of medicinal chemistry.

[3]  L. Johnson,et al.  The structure of P‐TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation , 2008, The EMBO journal.

[4]  Peter M Fischer,et al.  Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. , 2008, Trends in pharmacological sciences.

[5]  John T. Lis,et al.  Transcription Regulation Through Promoter-Proximal Pausing of RNA Polymerase II , 2008, Science.

[6]  O. Issinger,et al.  The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules. , 2008, Chemistry & biology.

[7]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[8]  Thomas S. Lin,et al.  Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. , 2007, Blood.

[9]  B. Peterlin,et al.  Controlling the elongation phase of transcription with P-TEFb. , 2006, Molecular cell.

[10]  Hiroshi Handa,et al.  P-TEFb-mediated phosphorylation of hSpt5 C-terminal repeats is critical for processive transcription elongation. , 2006, Molecular cell.

[11]  Giuseppe Zanotti,et al.  Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole. , 2005, Chemistry & biology.

[12]  Eric Westhof,et al.  Halogen bonds in biological molecules. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  L. Johnson,et al.  Alternative binding modes of an inhibitor to two different kinases. , 2003, European journal of biochemistry.

[14]  Andreas Rosenwald,et al.  Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol , 2001, Genome Biology.

[15]  L. Johnson,et al.  The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases , 1999, Nature Cell Biology.

[16]  D. Price,et al.  Identification of a Cyclin Subunit Required for the Function ofDrosophila P-TEFb* , 1998, The Journal of Biological Chemistry.

[17]  Frank H. Allen,et al.  The Nature and Geometry of Intermolecular Interactions between Halogens and Oxygen or Nitrogen , 1996 .

[18]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[19]  J. Darnell,et al.  The inhibition of DRB (5,6-dichloro-1-β-d-ribofuranosylbenzimidazole) of hnRNA and mRNA production in HeLa cells , 1976, Cell.

[20]  P. Afonine,et al.  research papers Acta Crystallographica Section D Biological , 2003 .